he merger of Carl Zeiss Ophthalmic Systems and Asclepion-Meditec has been unanimously approved by shareholders, with Zeiss holding 76% of the shares of the new combined firm, called Carl Zeiss Meditec AG, whose equity is being raised by e19.6 million to e25.8 million.
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.